Aromatase Inhibitors Drug-Drug Interaction Table

What Is the Aromatase Inhibitor Drug Class?

Aromatase inhibitors block CYP19A1, the enzyme that converts androgens (androstenedione, testosterone) into estrogens (estrone, estradiol) in peripheral tissues, adipose, liver, and the breast tumor microenvironment. Removing estrogen deprives hormone receptor-positive (HR+) tumors of their primary growth signal. The class divides into two structural types: non-steroidal triazoles (anastrozole, letrozole) and a steroidal irreversible inhibitor (exemestane).

Non-Steroidal Triazoles vs. Steroidal Exemestane

Anastrozole and letrozole bind CYP19A1 reversibly via a nitrogen-iron coordinate bond. Exemestane is a mechanism-based (suicide) inhibitor: it is converted by aromatase itself into a reactive intermediate that permanently inactivates the enzyme. This distinction matters for recovery time after discontinuation and for the interaction profile with CYP3A4 inducers.

Approved and Off-Label Indications

The FDA approves all three agents for HR+ breast cancer in postmenopausal women across adjuvant, extended adjuvant, and metastatic settings [1]. Off-label, anastrozole (1 mg/day or 0.5 mg every other day) and letrozole (2.5 mg/day or lower) are used by endocrinologists and men's-health prescribers to manage estradiol excess during testosterone replacement therapy, though no randomized controlled trial has established an optimal dosing protocol for this indication.

Pharmacokinetic Snapshot

| Agent | Bioavailability | Half-life | Primary CYP | Renal Dose Adj? | |---|---|---|---|---| | Anastrozole | ~83% | ~46 h | CYP3A4, CYP1A2, CYP2A6 | No | | Letrozole | ~99% | ~48 h | CYP2A6, CYP3A4 | No (mild-mod) | | Exemestane | ~42% (↑ with food) | ~27 h | CYP3A4, aldo-keto reductases | No |

Sources: FDA prescribing information for anastrozole [2], letrozole [3], and exemestane [4].

Core Drug-Drug Interaction Mechanisms

Understanding why an interaction occurs allows clinicians to predict novel combinations not yet in a published case series. Four mechanisms cover the vast majority of aromatase inhibitor DDIs.

Mechanism 1: CYP3A4 Induction or Inhibition

Anastrozole and letrozole are CYP3A4 substrates. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) accelerate their clearance and may reduce plasma concentrations by 30-50%, potentially undermining estrogen suppression. A pharmacokinetic study of rifampin co-administration with letrozole showed a 37% reduction in letrozole AUC [5]. Conversely, strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) may raise AI plasma levels, though the clinical significance is limited because the therapeutic index for estrogen suppression is wide at approved doses.

Mechanism 2: Pharmacodynamic Antagonism With Estrogens

Any exogenous estrogen, including combined oral contraceptives, menopausal hormone therapy (estradiol patches, gels, oral estradiol), and vaginal estrogens absorbed systemically, directly opposes aromatase inhibitor action. The FDA label for anastrozole states explicitly: "Anastrozole should not be co-administered with estrogen-containing therapies as these could diminish its pharmacological action" [2]. This is the highest-priority interaction in clinical practice.

Mechanism 3: Pharmacodynamic Antagonism With Tamoxifen

Co-prescribing tamoxifen with anastrozole was tested in the ATAC trial (N=9,366). The combination arm showed no superiority over tamoxifen monotherapy for disease-free survival, and anastrozole plasma concentrations were reduced by approximately 27% in women taking tamoxifen concurrently [6]. Sequential use (anastrozole after tamoxifen) is standard; concurrent use is not recommended by ASCO guidelines [7].

Mechanism 4: Additive Bone Demineralization

Estrogen deprivation from AIs accelerates bone resorption. Any drug that independently reduces bone mineral density (BMD) compounds fracture risk. The ATAC trial 5-year data reported a fracture rate of 11% with anastrozole vs. 7.7% with tamoxifen [6]. Stacking AIs with corticosteroids, depot medroxyprogesterone acetate, GnRH agonists, or PPIs (which impair calcium absorption by 20-40% at standard doses [8]) requires proactive bone protection.

Full Drug-Drug Interaction Table

The table below is organized by severity. Severity grades follow the standard pharmacovigilance convention: Major (avoid combination or requires mandatory monitoring/dose adjustment), Moderate (monitor closely, dose adjustment may be needed), Minor (awareness only, no routine action required).

Major Interactions (Avoid or Mandatory Management)

| Interacting Drug / Class | AI Affected | Mechanism | Clinical Effect | Management | |---|---|---|---|---| | Estradiol, combined OCs, estrogen-containing HRT | All AIs | PD antagonism at CYP19A1 substrate level | Reversal of estrogen suppression; loss of therapeutic effect | Contraindicated per FDA label [2][3][4] | | Tamoxifen (concurrent) | Anastrozole, letrozole | PD antagonism + CYP2D6-mediated reduction of AI plasma levels | 27% lower anastrozole AUC; no added efficacy in ATAC [6] | Avoid concurrent use; sequential therapy only per ASCO [7] | | Rifampin (rifampicin) | Letrozole, anastrozole | Strong CYP3A4 induction | 37% reduction in letrozole AUC [5] | Avoid; if unavoidable, consider alternative anti-TB regimen and monitor estradiol levels | | Carbamazepine | Letrozole, anastrozole | Strong CYP3A4 induction | Significant AI clearance increase; estradiol may not be adequately suppressed | Avoid; substitute lamotrigine or levetiracetam where clinically feasible | | Phenytoin / Fosphenytoin | Letrozole, anastrozole | Strong CYP3A4 + CYP2A6 induction | AI plasma trough reduction; estrogen breakthrough possible | Avoid; monitor serum estradiol if combination cannot be changed | | St. John's Wort (Hypericum perforatum) | All non-steroidal AIs | CYP3A4 induction (hyperforin component) | Unpredictable 30-50% AUC reduction [9] | Discontinue St. John's Wort; counsel patients explicitly at every visit |

Moderate Interactions (Monitor Closely)

| Interacting Drug / Class | AI Affected | Mechanism | Clinical Effect | Management | |---|---|---|---|---| | Corticosteroids (prednisone ≥5 mg/day chronic) | All AIs | Additive BMD loss; osteoclast activation | Fracture risk multiplied vs. Either agent alone | DEXA at baseline; calcium 1,200 mg/day + vitamin D 800-2,000 IU/day; consider bisphosphonate per ASCO guidelines [7] | | Proton pump inhibitors (omeprazole, pantoprazole) | All AIs | Reduced gastric acid impairs calcium carbonate absorption by ~40% [8] | Worsening AI-induced bone loss over time | Switch to calcium citrate (acid-independent absorption); maintain vitamin D sufficiency | | Warfarin | Anastrozole | CYP1A2/2C9 competition; possible alteration of warfarin metabolism | INR fluctuation reported in post-marketing data [2] | Check INR within 1-2 weeks of starting or stopping anastrozole; adjust warfarin dose accordingly | | Abiraterone acetate | Exemestane | Additive CYP17A1/CYP19A1 suppression | Profound androgen and estrogen depletion; cardiovascular and bone risk amplified | Monitor lipids, BMD, QTc; combination used in investigational breast cancer protocols only | | SSRIs (paroxetine, fluoxetine) | All AIs | Additive BMD loss via serotonin-mediated osteoblast suppression [10] | Incremental fracture risk, particularly hip and spine | Prefer sertraline or escitalopram (weaker CYP2D6 inhibition, less bone signal); monitor BMD | | Duloxetine | All AIs | Additive BMD loss pathway; CYP1A2 substrate competition | Similar to SSRI profile above | Monitor BMD annually; prefer alternative if musculoskeletal symptoms already present | | CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) | Letrozole, anastrozole | Inhibition of primary metabolic pathway | Possible 20-40% AI AUC increase; no toxicity threshold well-defined for AIs | Monitor for AI-related adverse effects (arthralgia, hot flashes); adjust if symptomatic | | Opioids (chronic, >90 mg MME/day) | All AIs | Opioid-induced androgen deficiency compounds estrogen suppression | Severe hypogonadism with heightened bone and cardiovascular risk | Monitor testosterone, estradiol, FSH/LH; minimize opioid dose; consider bone protection | | GnRH agonists (leuprolide, goserelin) | All AIs | Additive suppression of ovarian/testicular estrogen production | Estrogen <5 pg/mL common; bone loss accelerated vs. Either alone | Bisphosphonate prophylaxis in premenopausal women receiving combined therapy |

Minor Interactions (Awareness Only)

| Interacting Drug / Class | AI Affected | Mechanism | Clinical Effect | Management | |---|---|---|---|---| | Antacids (calcium carbonate, aluminum hydroxide) | All AIs | No direct PK effect on AIs; indirect calcium absorption competition with AI-prescribed calcium supplements | Suboptimal calcium supplementation if taken simultaneously | Separate antacid from calcium supplement by ≥2 hours | | Metformin | All AIs | Possible indirect reduction of aromatase expression in adipose via AMPK activation [11] | Theoretical additive estrogen suppression; clinically minor at standard doses | No routine action; monitor for unexpected estradiol nadir in diabetic patients | | NSAIDs (ibuprofen, naproxen) | All AIs | AI-induced arthralgia often treated with NSAIDs; no direct PK interaction | GI and renal risk from chronic NSAID use in older cancer patients | Prefer acetaminophen for AI arthralgia; limit NSAID duration | | Caffeine | Letrozole | CYP1A2 substrate competition (minor) | Negligible clinical effect at normal dietary intake | No action required |

Prescribing Considerations by Clinical Context

Breast Cancer Adjuvant Setting

ASCO 2022 guidelines recommend 5-10 years of adjuvant endocrine therapy for HR+ early breast cancer, with AIs preferred over tamoxifen in postmenopausal women [7]. The interaction checklist at initiation should cover: (1) concurrent estrogen sources, (2) bone-depleting drugs, (3) CYP3A4 inducers, and (4) anticoagulants. The MA.17R trial (N=1,918) showed that extending letrozole to 10 years reduced contralateral breast cancer risk (HR 0.42, 95% CI 0.22-0.81, P<0.01) [12], making long-term interaction vigilance essential across a decade of therapy.

Male Hypogonadism and TRT Protocols

Anastrozole 0.5-1 mg twice weekly or letrozole 2.5 mg twice weekly are used off-label in men on testosterone replacement therapy to prevent supraphysiologic estradiol. The most consequential interaction in this context is the additive bone risk when AIs are used in men who also receive GnRH agonists (for prostate cancer), chronic corticosteroids, or who have baseline low BMD. The Endocrine Society 2018 male hypogonadism guideline cautions that estradiol <10 pg/mL in men is associated with decreased BMD and impaired sexual function [13]. Over-suppression with AIs is a clinically meaningful risk, not just an abstract one.

Premenopausal Women: Ovarian Suppression Combinations

In premenopausal HR+ breast cancer, combining a GnRH agonist (goserelin 3.6 mg SC monthly) with exemestane is supported by the SOFT/TEXT trials (N=4,690 combined), which showed a 7-year distant recurrence-free survival of 85.9% with exemestane plus ovarian suppression vs. 78.9% for tamoxifen plus ovarian suppression [14]. This combination produces near-castrate estradiol levels and substantially accelerates bone loss. All premenopausal women on this regimen require DEXA at baseline, calcium, vitamin D, and strong consideration of a bisphosphonate or denosumab per ASCO guidance [7].

Fertility Preservation Context

Letrozole 2.5-5 mg/day on cycle days 3-7 is used off-label for ovulation induction and fertility preservation. The ASCO 2018 fertility preservation guideline supports its use in hormone-sensitive cancers before chemotherapy [15]. Interaction concerns in this setting are brief (5-day course), but concurrent use of other ovulation inducers or gonadotropins requires monitoring for ovarian hyperstimulation.

Monitoring Protocol for Patients on Aromatase Inhibitors

Laboratory Monitoring

• Estradiol (E2): Baseline, then every 3-6 months in TRT/off-label use to confirm adequate but not excessive suppression. Target E2 in men on TRT: 20-40 pg/mL per clinical consensus; target in breast cancer: <10 pg/mL (postmenopausal range).
• Lipid panel: Anastrozole worsened the total cholesterol:HDL ratio vs. Tamoxifen in ATAC [6]. Check at baseline and annually.
• Liver function tests: Letrozole and anastrozole are hepatically metabolized. Check at baseline; repeat if hepatotoxic drugs are added.
• Complete blood count: Not routinely required but check if combining with cytotoxic agents.

Bone Health Monitoring

ASCO 2022 recommends DEXA at baseline and every 1-2 years for all patients starting AI therapy [7]. The SABRE trial (N=234) demonstrated that zoledronic acid 4 mg IV every 6 months prevented AI-associated bone loss over 3 years in postmenopausal women with baseline osteopenia [16]. If T-score is below -2.0 at baseline, start an antiresorptive agent before the first AI dose.

Symptom Monitoring

AI-induced arthralgia affects 35-50% of patients and is the leading cause of non-adherence [17]. Arthralgia is not a DDI, but prescribers should distinguish it from NSAID-interaction-related GI complaints, which can appear similar in patient self-report.

Special Populations

Hepatic Impairment

Anastrozole and letrozole exposures increase in severe hepatic impairment (Child-Pugh C). The anastrozole FDA label reports a 30% AUC increase in subjects with cirrhosis [2]. No dose adjustment is defined, but closer estradiol monitoring and avoidance of additional hepatotoxic DDI partners is warranted.

Renal Impairment

None of the three AIs require dose adjustment for renal impairment based on current prescribing information [2][3][4]. Letrozole is <10% renally excreted unchanged. Exemestane metabolites accumulate in severe renal failure (eGFR <30 mL/min/1.73m²), though the clinical significance has not been formally studied in a dedicated trial.

Older Adults (Age ≥70)

Polypharmacy is the norm in this population. The most common problematic combinations in older breast cancer patients are AIs plus PPIs (near-universal use) plus low-dose corticosteroids for comorbidities. Each pairing adds incremental bone risk. A comprehensive medication review at AI initiation using the Beers Criteria framework is standard practice, and the American Geriatrics Society 2023 Beers Criteria update lists AI-related bone risk as a consideration for this population [18].

Patient Counseling Points

Patients starting an aromatase inhibitor should be told:

1. Avoid all estrogen-containing products: prescription HRT, over-the-counter "bioidentical" creams, phytoestrogen supplements in pharmacologic doses, and estrogen-containing vaginal preparations absorbed systemically.
2. Tell every prescriber and pharmacist they are on an AI before any new drug is started.
3. Take calcium citrate (not carbonate if on a PPI) 500 mg twice daily with food, and vitamin D3 800-2,000 IU daily.
4. Report new joint pain or stiffness within the first 6 weeks. It may be AI-induced arthralgia, which is manageable and should not prompt unilateral discontinuation.
5. St. John's Wort is not a harmless supplement in this context. It could reduce the AI's effect on estrogen.

The ASCO 2022 guideline states: "Patients should be counseled about the risk of bone loss and fractures associated with aromatase inhibitor therapy, and appropriate preventive measures should be implemented at the time of AI initiation" [7].